Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECHO: Exenatide in Hypothalamic Obesity
NCT02664441Phase 3Completed
- Sponsor
- Seattle Children's
- Start
- Mar 2016
- Primary completion
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypothalamic obesity (HO) comparing Exenatide with Placebo (2 arms). Primary endpoint: Percent Change of Body Mass Index at 36 weeks. Started Mar 2016; status: completed.
02
Drugs
exenatide
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on NCT02664441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664441.